Financial FlexibilityThe capital restructuring provides Heron Therapeutics the flexibility to continue operating and grow its key products Zynrelef and Aponvie.
Product LaunchMomentum is building ahead of expanded commercial initiatives and the launch of a dedicated Zynrelef sales team in the third quarter of 2025.
Revenue GrowthHeron reiterated its full-year revenue guidance of $153M to $163M, and the company has reported $76M in 1H25 revenue, making the guidance achievable.